Amyotrophic lateral sclerosis & frontotemporal degeneration
Pridopidine treatment in ALS: subgroup analyses from the HEALEY ALS Platform trial.
Michal Geva, Y Paul Goldberg, Melanie L Leitner, Andres Cruz-Herranz, Randal Hand, Kelly Chen, Noga Gershoni Emek, Andrew M Tan, Sabrina Paganoni, James D Berry, Eric A Macklin, Jeremy M Shefner, Merit E Cudkowicz, Michael R Hayden
Published: 202510.1080/21678421.2025.2597935
Abstract
Objectives: Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease with limited treatment options. Pridopidine, a selective sigma-1 receptor agonist, was evaluated in Regimen D of the HEALEY ALS Platform Trial. Although the pr…
Preview only. Read the full abstract at the source